Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (15)

2023

  1. A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

  2. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1

    Journal of Infectious Diseases

  4. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

    Frontiers in Public Health, Vol. 11

2022

  1. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953

  2. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

    Acta Dermato-Venereologica, Vol. 102

2021

  1. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

    Infectious Diseases and Therapy, Vol. 10, Núm. 1, pp. 347-362

2020

  1. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2019

  1. Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide

    Infection, Vol. 47, Núm. 1, pp. 115-119

2018

  1. Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges

    International Journal of STD and AIDS, Vol. 29, Núm. 9, pp. 933-936

  2. Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis

    BioDrugs, Vol. 32, Núm. 3, pp. 281-291

  3. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

2017

  1. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

2016

  1. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013

    Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 1, pp. 137-144

  2. Immune reconstitution inflammatory syndrome in an HIV-infected patient using subcutaneous silicone fillers

    AIDS, Vol. 30, Núm. 16, pp. 2561-2563